Skip to main content
. 2016 Sep 30;7(43):69149–69158. doi: 10.18632/oncotarget.12381

Figure 2. MEK-162 treatment reduces POMC transcription and ACTH secretion in murine and human pituitary corticotroph tumor cells.

Figure 2

A., AtT20 cells were transfected with a POMC promoter-luciferase reporter. 24 h later, cells were treated with 20 μM and 40 μM MEK-162 in Opti-MEM for 48 and 72 h after which luciferase activities were measured and presented as fold change compared to controls. B., Quantitative PCR (Q-PCR) was used to assess the changes of POMC mRNA following 20 μM and 40 μM MEK-162 treatment for 24 h in Opti-MEM. C., ACTH levels were measured in supernatants from murine AtT20 cells by ELISA assay after 40 μM and 80 μM MEK-162 treatment for 48 h. (D-F), The inhibitory effects of MEK-162 treatment were measured on cell proliferation D., POMC mRNA E. and ACTH secretion F. in primary culture of freshly resected human corticotroph tumors (n = 5). Each bar depicts the mean ± standard error of triplicate tests. * p < 0.05; ** p < 0.01; *** p < 0.005. Data shown are representative of at least three independently performed experiments.